SearchDictionaryMobileLogin

Intracranial Arteriosclerosis (Cerebral Atherosclerosis)

243  relevant articles (5 outcomes, 28 trials/studies) found for this Disease

Description: Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA, (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.

Also Known As:
Cerebral Atherosclerosis; Cerebral Arteriosclerosis; Intracranial Atherosclerosis; Arterioscleroses, Cerebral; Arterioscleroses, Intracranial; Arteriosclerosis, Cerebral; Arteriosclerosis, Intracranial; Atheroscleroses, Cerebral; Atheroscleroses, Intracranial; Atherosclerosis, Cerebral; Atherosclerosis, Intracranial; Cerebral Arterioscleroses; Cerebral Atheroscleroses; Intracranial Arterioscleroses; Intracranial Atheroscleroses

Relationship Network

Disease Context: Research Results

Related Diseases

1. Syndrome
2. Intermittent Claudication
3. Stroke (Strokes)
4. Pathologic Constriction (Stenosis)
5. Hypertension (High Blood Pressure)

Experts

1. Higashida, Randall T: 4 articles (06/2006 - 01/2004)
2. Meyers, Philip M: 3 articles (06/2006 - 01/2004)
3. Barr, John D: 2 articles (10/2005 - 10/2005)
4. Society of Interventional Radiology: 2 articles (10/2005 - 10/2005)
5. American Society of Interventional and Therapeutic Neuroradiology: 2 articles (10/2005 - 10/2005)
6. Duckwiler, Gary R: 2 articles (10/2005 - 10/2005)
7. American Society of Neuroradiology: 2 articles (10/2005 - 10/2005)
8. Wojak, Joan C: 2 articles (10/2005 - 10/2005)
9. Sacks, David: 2 articles (10/2005 - 10/2005)
10. Tian, J: 2 articles (05/2004 - 02/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Intracranial Arteriosclerosis:
1. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
2. EndostatinsIBA
01/01/2005 - "CONCLUSIONS: A predominance of the inhibitor endostatin within the endogenous angiogenic response is associated with a greater extent and risk of recurrence of symptomatic intracranial atherosclerosis, suggesting that angiogenesis may be beneficial in this condition."
01/01/2005 - "Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence."
01/01/2005 - "We aimed to investigate the relationship between the pro-angiogenic vascular endothelial growth factor (VEGF) and the anti-angiogenic endostatin, and the extent and risk of recurrence of symptomatic intracranial atherosclerosis"
01/01/2005 - "Diabetes mellitus (OR, 6.04; CI, 1.1 to 32.2; P=0.03) and a higher endostatin/VEGF ratio (OR, 15.7; CI, 2.2 to 112.3; P=0.006) were independently associated with a greater extent of intracranial atherosclerosis"
01/01/2005 - "Studies performed by our group in patients with symptomatic intracranial large-artery atherosclerosis have shown that: (1) C-reactive protein predicts its progression and recurrence, suggesting that inflammation may play a deleterious role in this condition; (2) a high level of the anti-angiogenic endostatin is also associated with a progressive and recurrent intracranial atherosclerosis, which might support a beneficial role for angiogenesis in this group of patients; and (3) elevated lipoprotein(a) concentration and diabetes mellitus characterize those patients with a higher number of intracranial stenoses."
Order ALL the reference details at left...
3. PapaverineIBA
4. TaurineFDA Link
5. Warfarin (Coumadin)FDA LinkGeneric
6. glucuronyl glucosamine glycan sulfate (Vessel)IBA
7. CholesterolIBA
8. Retinaldehyde (Retinal)IBA
9. Apolipoproteins E (ApoE)IBA
10. Aminophylline (Carine)FDA LinkGeneric

Therapies and Procedures

1. Angioplasty (Angioplasties)
2. Stents
3. Balloon Angioplasty (Angioplasty, Transluminal)
4. Baths
5. Electronarcosis (Electrosleep)

Best Treatments:
Research Summary Report
on Intracranial Arteriosclerosis
*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 5 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone